5 Results for "

EBV-IN-1

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "EBV-IN-1" in MCE Product Catalog:

Cat. No.: HY-175683
Target:  

EBV HIV

Research Areas:  

Infection

EBV-IN-1 (Compound 15) is an antiviral agent. EBV-IN-1 has a potent antiviral activity against EBV with a EC50 of 0.17  μM. EBV-IN-1 also shows inhibitory effects on HIV (EC50: 20.8 μM). EBV-IN-1 can be used for EBV and HIV infections research [1].
loading...
    loading...
Cat. No.: HY-119098
CAS No.: 827591-02-6
Purity:  99.8%
Target:  

EBV HPV

Research Areas:  

Infection

GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes [1].
loading...
    loading...
Cat. No.: HY-P10497
CAS No.: 200124-17-0
Target:  

Bacterial

Research Areas:  

Infection Inflammation/Immunology

EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases [1].
loading...
    loading...
Cat. No.: HY-P10497A
Target:  

Bacterial

Research Areas:  

Infection Inflammation/Immunology

EBV BZLF1 (190-197) TFA is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) TFA is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) TFA are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) TFA can be used to study autoimmune diseases [1].
loading...
    loading...
Cat. No.: HY-N9865
CAS No.: 155899-92-6
cis-Martynoside is a phenylpropanoid glycoside. Cis-Martynoside, in a mixture with trans-Martynoside, effectively inhibits the early activation of the lytic cycle of Epstein-Barr virus (EBV) and reduces the expression of Rta protein. cis-Martynoside can be used in research on EBV infection .
loading...
    loading...